Sugi Predict

Sugi Predict / Compounds / SCHEMBL1014038

SCHEMBL1014038

SCHEMBL1014038

Cc1cccc(Oc2ccc(N)cn2)c1C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KEAP1 Q14145 1/20 1.00
▸ MEN1 O00255 5/20 0.58
▸ KMT2A Q03164 5/20 0.58
▸ KDM4E B2RXH2 5/20 0.51
▸ ALDH1A1 P00352 2/20 0.51
▸ BRCA1 P38398 1/20 0.51
▸ HBB P68871 1/20 0.51
▸ HSD17B10 Q99714 1/20 0.51
▸ NUDT1 P36639 1/20 0.49
▸ POLB P06746 2/20 0.49
▸ RAB9A P51151 2/20 0.45
▸ DHFR P00374 1/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ CYP2D6 P10635 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ LMNA P02545 1/20 0.44
▸ TP53 P04637 1/20 0.44
▸ TSHR P16473 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4064464 0.87 KEAP1 (0.77) KEAP1MEN1KMT2AKDM4EALDH1A1
SCHEMBL1980444 0.86 KEAP1 (0.75) KEAP1MEN1KMT2AKDM4EALDH1A1
Hydrochloric Acid SCHEMBL13721237 0.84 KEAP1 (0.73) KEAP1MEN1KMT2AKDM4EALDH1A1
SCHEMBL14654786 0.83 KEAP1 (0.71) KEAP1MEN1KMT2AKDM4EALDH1A1
SCHEMBL1979598 0.81 KEAP1 (0.69) KEAP1MEN1KMT2AKDM4EALDH1A1
SCHEMBL3802138 0.80 KEAP1 (0.66) KEAP1MEN1KMT2AKDM4EALDH1A1
SCHEMBL13561341 0.78 KEAP1 (0.64) KEAP1MEN1KMT2AKDM4EALDH1A1
SCHEMBL4070376 0.77 KEAP1 (0.63) KEAP1MEN1KMT2AKDM4EALDH1A1
SCHEMBL23720003 0.77 MEN1 (0.66) KEAP1MEN1KMT2AKDM4EALDH1A1
SCHEMBL12593846 0.77 KEAP1 (0.62) KEAP1MEN1KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125381-A1 NOVEL Kv3 CHANNEL MODULATORS MERCK SHARP & DOHME LLC (US) 2026-05-07 — — US disclosed
EP-4604945-A2 NOVEL KV3 CHANNEL MODULATORS Merck Sharp & Dohme LLC (US) 2025-08-27 — — EP disclosed
WO-2024086061-A2 NOVEL KV3 CHANNEL MODULATORS MERCK SHARP & DOHME LLC (US) 2024-04-25 — — WO disclosed
US-11180461-B2 Triazoles as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2021-11-23 — — US disclosed
EP-2852589-B1 TRIAZOLES AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LTD (GB) 2021-04-28 — — EP disclosed
US-20200172496-A1 TRIAZOLES AS KV3 INHIBITORS AUTIFONY SRL (IT) 2020-06-04 — — US disclosed
US-20200163964-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2020-05-28 — — US disclosed
US-20200163964-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2020-05-28 — — US disclosed
US-10632118-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2020-04-28 — — US disclosed
US-10632118-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2020-04-28 — — US disclosed
WO-2009108657-A2 HETEROARYL DERIVATIVES AS CFTR MODULATORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-09-03 — — WO disclosed
US-20090221597-A1 HETEROARYL DERIVATIVES AS CFTR MODULATORS VERTEX PHARMACEUTICALS INCORPORATED 2009-09-03 — — US disclosed
US-20090221597-A1 HETEROARYL DERIVATIVES AS CFTR MODULATORS VERTEX PHARMACEUTICALS INCORPORATED 2009-09-03 — — US disclosed
US-20090221597-A1 HETEROARYL DERIVATIVES AS CFTR MODULATORS VERTEX PHARMACEUTICALS INCORPORATED 2009-09-03 — — US disclosed
EP-1066261-B1 PYRIDINE DERIVATIVE AND PHARMACEUTICAL CONTAINING THE SAME OTSUKA PHARMA CO LTD (JP) 2005-11-23 — — EP disclosed
CN-1115334-C Pyridine derivative and medicine containing the same OTSUKA PHARMA CO LTD (JP) 2003-07-23 — — CN disclosed
US-6511995-B1 Inhibits collagen synthesis, which is useful for prophylaxis or treatment of fibrosis OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2003-01-28 — — US disclosed
CN-1294581-A Pyridine derivative and pharmaceutical contg. same OTSUKA PHARMA CO LTD (JP) 2001-05-09 — — CN disclosed
EP-1066261-A1 PYRIDINE DERIVATIVE AND PHARMACEUTICAL CONTAINING THE SAME OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2001-01-10 — — EP disclosed
WO-1999048871-A1 PYRIDINE DERIVATIVE AND PHARMACEUTICAL CONTAINING THE SAME OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1999-09-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10632118-B2 Imidazolidinedione derivatives KCND3, KCNK3, KCNA3 KEAP1 3193/4885MEN1 1190/4885KMT2A 530/4885
US-20200172496-A1 TRIAZOLES AS KV3 INHIBITORS KCNA3, KCNN3, KCNK3 KEAP1 1251/4885MEN1 2340/4885KMT2A 984/4885
US-20260125381-A1 NOVEL Kv3 CHANNEL MODULATORS KCNN3, KCNA3, KCNQ3 KEAP1 1499/4885MEN1 3334/4885KMT2A 2229/4885
US-11180461-B2 Triazoles as Kv3 inhibitors KCNA3, KCNN3, KCNK3 KEAP1 1251/4885MEN1 2340/4885KMT2A 984/4885
US-20200163964-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 KEAP1 3193/4885MEN1 1190/4885KMT2A 530/4885
US-20090221597-A1 HETEROARYL DERIVATIVES AS CFTR MODULATORS CFTR, ABCB1, ABCD3 KEAP1 143/4885MEN1 4840/4885KMT2A 4386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.